{"product_id":"tesa10-ip5","title":"Tesa10+Ip5","description":"\u003ch3\u003eTesa10 + IP5 (Tesamorelin 10mg + Ipamorelin 5mg Blend)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eFull Research Introduction \u0026amp; Administration Guide \u003c\/span\u003e\u003cstrong\u003eIMPORTANT DISCLAIMER: For laboratory research use only. Not approved for human injection, clinical treatment or consumption. All dosing information is summarized from published preclinical literature purely for experimental reference.\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003eIndustry shorthand explanation: Tesa = Tesamorelin (GHRH analog) IP5 = Ipamorelin 5mg (GHRP agonist) This dual-peptide lyophilized blend combines Tesamorelin \u0026amp; Ipamorelin inside one vial.\u003c\/div\u003e\n\u003ch3\u003e1. Basic Overview\u003c\/h3\u003e\n\u003ch3\u003eIndividual Peptide Information\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTesamorelin (Tesa)\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCAS Number: 218949-48-5\u003c\/li\u003e\n\u003cli\u003eMolecular Weight: 5135.9 Da\u003c\/li\u003e\n\u003cli\u003eClassification: Synthetic Growth Hormone-Releasing Hormone (GHRH) analog\u003c\/li\u003e\n\u003cli\u003eCore trait: Stimulates pituitary pulsatile endogenous GH secretion; famous for visceral adipose tissue lipolysis research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eIpamorelin (IP5)\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCAS Number: 170851-70-4\u003c\/li\u003e\n\u003cli\u003eMolecular Weight: 711.86 Da\u003c\/li\u003e\n\u003cli\u003eClassification: Selective Growth Hormone Releasing Peptide (GHRP) agonist\u003c\/li\u003e\n\u003cli\u003eCore trait: Stimulates GH release without significant elevation of cortisol or prolactin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eBlend Profile: Tesa10+IP5\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eStandard Specification:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e10mg Tesamorelin + 5mg Ipamorelin per single vial\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eForm: Lyophilized white crystalline powder\u003c\/li\u003e\n\u003cli\u003eSynergy Principle: GHRH (Tesamorelin) + GHRP (Ipamorelin) work via two separate receptor pathways to amplify growth hormone pulsatile release. Together they achieve stronger GH \u0026amp; IGF-1 elevation compared to single-peptide administration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e2. Mechanism of Action\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin (GHRH Pathway)\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eBinds pituitary GHRH receptors, drives natural, pulsatile growth hormone synthesis and secretion. Primarily researched for visceral fat breakdown, lipid metabolism regulation and body composition modulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIpamorelin (GHRP Pathway)\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eActivates ghrelin receptors in the pituitary gland to trigger GH release. It exhibits minimal impact on adrenocorticotropic hormone, cortisol and prolactin levels.\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCombined Synergistic Effects\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003eAmplified pulsatile GH secretion, superior to single peptide research models\u003c\/li\u003e\n\u003cli\u003eEnhanced lipolysis, especially targeting visceral abdominal fat\u003c\/li\u003e\n\u003cli\u003eImproved connective tissue repair, muscle maintenance research\u003c\/li\u003e\n\u003cli\u003eBalanced endocrine profile with lower risk of excess cortisol elevation compared to other GHRP combinations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e3. Main Research Applications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eBody composition \u0026amp; visceral fat metabolism research\u003c\/li\u003e\n\u003cli\u003eEndocrine and growth hormone pathway pharmacology studies\u003c\/li\u003e\n\u003cli\u003eSkeletal muscle maintenance \u0026amp; soft tissue recovery experiments\u003c\/li\u003e\n\u003cli\u003eAging, longevity and metabolic homeostasis research\u003c\/li\u003e\n\u003cli\u003eComparative studies: Single GHRH \/ single GHRP vs dual agonist blends\u003c\/li\u003e\n\u003cli\u003eLipid profile regulation and insulin sensitivity experimental models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e4. Reconstitution Instructions (Lyophilized Blend Vial)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eStandard Vial: 10mg Tesamorelin + 5mg Ipamorelin\u003c\/span\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eLet vial reach room temperature; disinfect rubber stopper with alcohol wipe.\u003c\/li\u003e\n\u003cli\u003eSlowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cdiv\u003eRecommended mixing scheme: Add\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e3mL BAC water\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eFinal concentration: Tesamorelin: 3.33 mg \/ mL Ipamorelin: 1.67 mg \/ mL\u003c\/div\u003e\n\u003col start=\"3\"\u003e\n\u003cli\u003eGently rotate the vial to dissolve powder.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDO NOT shake violently to prevent peptide aggregation and degradation.\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eQualified solution is clear and colourless.\u003c\/li\u003e\n\u003cli\u003eStorage Requirements\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003eUnreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.\u003c\/li\u003e\n\u003cli\u003eReconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDo not freeze reconstituted liquid.\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003eSpecial Note: Tesamorelin is prone to aggregation. Avoid repeated temperature fluctuations.\u003c\/div\u003e\n\u003ch3\u003e5. Research Administration Protocols\u003c\/h3\u003e\n\u003ch3\u003ePrimary Route: Subcutaneous Injection\u003c\/h3\u003e\n\u003ch3\u003eReference Experimental Dosage (Blend whole-vial ratio)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLow starting tolerance dose:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e0.3mL solution once daily\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eStandard experimental dose:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e0.4–0.6mL solution once daily\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMax researched dose: 0.7mL solution once daily\u003c\/li\u003e\n\u003cli\u003eRecommended timing: Evening, 90–120 minutes after last meal (consistent with GH natural circadian rhythm)\u003c\/li\u003e\n\u003cli\u003eInjection site: Lower abdomen, anterior thigh or upper arm; rotate injection positions regularly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eReference Experimental Cycle\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eDaily administration for 8–12 weeks, followed by a minimum 4-week washout pause before initiating a new research cycle.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e6. Precautions \u0026amp; Observed Adverse Reactions\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003ePure laboratory research compound. Not authorized for human therapeutic use.\u003c\/li\u003e\n\u003cli\u003eStrict aseptic technique required during reconstitution to prevent microbial contamination.\u003c\/li\u003e\n\u003cli\u003eDiscard solution immediately if turbidity, precipitation or discoloration appears.\u003c\/li\u003e\n\u003cli\u003eCommon dose-dependent mild observed effects: transient redness\/itching at injection site, mild temporary bloating.\u003c\/li\u003e\n\u003cli\u003eAvoid pairing with other GH secretagogues simultaneously unless defined by experimental protocol.\u003c\/li\u003e\n\u003cli\u003eLong-term high-dose safety data remains limited; all research must comply with laboratory ethics standards.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr\u003e\n\u003ch3\u003eShort Version (For Product Page \/ Customer Direct Message)\u003c\/h3\u003e\n\u003ch3\u003eTesa10 + IP5 (Tesamorelin 10mg + Ipamorelin 5mg Blend)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTesa10+IP5 is a lyophilized dual peptide blend combining Tesamorelin (GHRH analog) and Ipamorelin (selective GHRP agonist). The two peptides act through complementary pathways to stimulate pulsatile growth hormone release. It is widely used for laboratory research focused on visceral fat metabolism, body composition, muscle maintenance and endocrine regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eMix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReference Subcutaneous Research Dosage\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003e0.3–0.6mL reconstituted solution, administered once daily in the evening. Gradual low-dose initiation is recommended.\u003c\/span\u003e\u003c\/p\u003e","brand":"我的商店","offers":[{"title":"15mg*10vials","offer_id":53703711818028,"sku":null,"price":98.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0979\/1406\/1100\/files\/8999eeb35cc8178646d664c1d85dc5d13ef14c20dc9c11f3be25473752abe8e8.png?v=1786600569","url":"https:\/\/0rw2.com\/products\/tesa10-ip5","provider":"0rw2.com","version":"1.0","type":"link"}